<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118933</url>
  </required_header>
  <id_info>
    <org_study_id>K19406-JS001-ISS-141</org_study_id>
    <nct_id>NCT04118933</nct_id>
  </id_info>
  <brief_title>A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer</brief_title>
  <official_title>An Exploratory Study for PD-1 Antibody JS001 in Participants With Microsatellite Instability-high (MSI-H) Advanced or Recurrent Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xu jianmin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the efficacy of PD-1 antibody JS001 in the treatment of participants with&#xD;
      microsatellite instability-high (MSI-H) advanced or recurrent colorectal cancer, so as to&#xD;
      provide sufficient evidence for MSI-H as a biomarker of PD-1/PD-L1 inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">July 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>12 Weeks from the drug firstly being taken</time_frame>
    <description>The 12 week objective response will be measured according to RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>MSI-H advanced colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS001</intervention_name>
    <description>JS001 240mg, Q3W</description>
    <arm_group_label>MSI-H advanced colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fully understand the study and sign informed consent voluntarily;&#xD;
&#xD;
          -  Histologically confirmed advanced or recurrent colorectal cancer, and MSI detection&#xD;
             identified MSI-H;&#xD;
&#xD;
          -  Patients who have previously received first-line or above chemotherapy or targeted&#xD;
             therapy and failed to the treatment or experienced recurrence;&#xD;
&#xD;
          -  At least one measurable lesion (RECIST 1.1);&#xD;
&#xD;
          -  Agree to provide tumor tissue samples and Pathology reports related to the specimens;&#xD;
&#xD;
          -  Aged 18 to 75 years, gender not limited;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) performance status(PS) 0-1; 8. Expected&#xD;
             survival â‰¥3 months;&#xD;
&#xD;
          -  Laboratory test values must meet the following standards within 7 days before&#xD;
             enrollment;&#xD;
&#xD;
          -  Women of reproductive age must confirm that the serum pregnancy test is negative and&#xD;
             agree to use effective contraceptive measures during the study drug use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia;&#xD;
&#xD;
          -  Had major surgery or had not fully recovered from previous surgery within 4 weeks&#xD;
             before enrollment;&#xD;
&#xD;
          -  central nervous system(CNS) metastases;&#xD;
&#xD;
          -  Bone metastases;&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated&#xD;
             drainage (once a month or more frequently) allow the patient to have a catheter&#xD;
             indwelling;&#xD;
&#xD;
          -  Having a history of idiopathic pulmonary fibrosis, organic pneumonia;&#xD;
&#xD;
          -  Uncontrolled active infection, including but not limited to acute pneumonia;&#xD;
&#xD;
          -  Have other malignant tumors at the same time;&#xD;
&#xD;
          -  The patient has any active autoimmune diseases or a history of autoimmune diseases;&#xD;
&#xD;
          -  Liver diseases of known clinical significance, including active viral viral hepatitis,&#xD;
             alcoholic hepatitis or other hepatitis, cirrhosis, fatty liver and hereditary liver&#xD;
             diseases.&#xD;
&#xD;
          -  Previous use of anti-PD-1 antibody, anti-PD-l1 antibody, anti-PD-l2 antibody or&#xD;
             anti-CTLA-4 antibody;&#xD;
&#xD;
          -  Patients with active tuberculosis (TB);&#xD;
&#xD;
          -  Received systemic immunosuppressive within 4 weeks prior to day 1 of the first cycle;&#xD;
&#xD;
          -  Pregnancy test positive;&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  A history of severe allergy, anaphylaxis or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins;&#xD;
&#xD;
          -  Those who are known to be allergic to biological drugs produced by hamster ovary cells&#xD;
             in China, or to citric acid monohydrate, sodium citrate dihydrate, mannitol and&#xD;
             polysorbate (components of the experimental drugs);&#xD;
&#xD;
          -  Patients who have previously received allogeneic stem cells or parenchymal organ&#xD;
             transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu, MD</last_name>
    <phone>+8613501984869</phone>
    <email>xujmin@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dexiang Zhu, MD</last_name>
      <phone>+8613764353275</phone>
      <email>shzhudx@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Deputy director of the colorectal cancer center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

